"Tempus announced its Pan-Cancer HRD-RNA algorithm today, an AI-driven tool that identifies Homologous Recombination Deficiency using RNA analysis rather than traditional DNA tests. This approach provides a real-time snapshot of tumor biology, helping doctors identify patients likely to respond to platinum-based chemotherapy or PARP inhibitors. In real-world validation, patients with HRD-RNA positive metastatic pancreatic cancer showed significantly lower mortality risk compared to those receiving non-platinum therapies. The algorithm is currently available for research use, with clinical availability expected later in 2026."
"What Analysts Say Wall Street remains bullish despite recent volatility. The consensus analyst target sits at $85.69, representing nearly 50% upside from current levels. Analysts cite 2 Strong Buy and 5 Buy ratings, highlighting Tempus's accelerating revenue growth and expanding AI-driven diagnostics platform. The HRD-RNA launch signals continued innovation heading into earnings, but the stock remains down 18.54% over the past month. Tuesday's report will provide more clarity on whether today's momentum is supported by lasting fundamental strength or represents a short-term move ahead of results."
Tempus unveiled the Pan-Cancer HRD-RNA algorithm, an AI-driven tool that identifies homologous recombination deficiency using RNA analysis instead of DNA tests. The algorithm delivers a real-time snapshot of tumor biology to help clinicians identify patients likely to respond to platinum-based chemotherapy or PARP inhibitors. Real-world validation showed HRD-RNA–positive metastatic pancreatic cancer patients had significantly lower mortality risk versus patients receiving non-platinum therapies. The assay is available for research use now and is expected to reach clinical availability later in 2026. Tempus reported preliminary Q4 revenue of $367 million, up 83% year-over-year, with total contract value exceeding $1.1 billion, and analysts remain broadly bullish with a consensus price target implying substantial upside.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]